HORMONE THERAPY COSTS:
INDIA AND CHINA VS USA
For patients without insurance or facing high co-pays, India offers the same hormone therapy drugs at 90โ98% lower cost โ with equivalent quality from WHO-prequalified manufacturers.
analyticsAt a Glance
- check_circleLetrozole: $4โ8/month in India vs $300โ500 in the USA
- check_circleEnzalutamide: $400โ800/month in India vs $8,000โ10,000 in the USA
- check_circlePalbociclib: $500โ800/month in India vs $12,000โ14,000 in the USA
- check_circleCancerFax coordinates legal access to Indian generics with verified quality and prescribing support
Breast Cancer Hormone Therapy: Drug-by-Drug Cost Comparison
Monthly cost estimates for the most commonly prescribed breast cancer hormone therapies โ India generic vs USA branded.
| Drug | Indication | USA (Branded) | India (Generic) | Savings |
|---|---|---|---|---|
| Tamoxifen 20mg/day | ER+ breast cancer โ pre/post-menopausal | $100โ200/mo | $4โ8/mo | ~97% |
| Letrozole 2.5mg/day | ER+ breast cancer โ post-menopausal | $300โ500/mo | $4โ8/mo | ~98% |
| Anastrozole 1mg/day | ER+ breast cancer โ post-menopausal | $200โ400/mo | $5โ10/mo | ~97% |
| Exemestane 25mg/day | ER+ breast cancer โ post-menopausal | $250โ450/mo | $8โ15/mo | ~96% |
| Fulvestrant 500mg inj x2/mo | ER+ HER2- advanced, post-menopausal | $6,000โ8,000/mo | $300โ600/mo | ~93% |
| Palbociclib 125mg/day | ER+ HER2- advanced + AI (CDK4/6i) | $12,000โ14,000/mo | $500โ900/mo | ~94% |
| Ribociclib 600mg/day | ER+ HER2- advanced + AI (CDK4/6i) | $13,000โ15,000/mo | $600โ1,000/mo | ~93% |
| Abemaciclib 150mg BD | ER+ HER2- advanced/adjuvant (CDK4/6i) | $13,000โ15,000/mo | $500โ900/mo | ~94% |
| Elacestrant 345mg/day | ESR1-mutant ER+ advanced (SERD) | $6,000โ8,000/mo | Limited availability | N/A |
| Alpelisib 300mg/day | PIK3CA-mutant ER+ + fulvestrant | $22,000โ25,000/mo | $800โ1,500/mo | ~94% |
Prostate Cancer Hormone Therapy: Drug-by-Drug Cost Comparison
Monthly cost estimates for ADT and next-generation hormone therapies for prostate cancer.
| Drug | Indication | USA (Branded) | India (Generic) | Savings |
|---|---|---|---|---|
| Leuprolide 3-month depot | ADT โ LHRH agonist | $1,500โ2,500/inj | $150โ300/inj | ~87% |
| Goserelin 3-month implant | ADT โ LHRH agonist | $1,500โ2,500/implant | $100โ200/implant | ~90% |
| Enzalutamide 160mg/day | mCRPC, nmCRPC โ AR antagonist | $8,000โ10,000/mo | $400โ800/mo | ~92% |
| Abiraterone 1000mg/day + pred | mCRPC, mHSPC โ CYP17A1 inhibitor | $6,000โ8,000/mo | $100โ200/mo | ~97% |
| Darolutamide 1200mg/day | nmCRPC โ AR antagonist | $8,000โ10,000/mo | $500โ900/mo | ~91% |
| Apalutamide 240mg/day | nmCRPC, mHSPC โ AR antagonist | $7,000โ9,000/mo | $400โ800/mo | ~92% |
The Scale of the Cost Difference
- 97%Average savings on aromatase inhibitors โ India vs USA brandedLetrozole, anastrozole, and exemestane: $4โ15/month in India vs $200โ500/month in USA.
- $11,500+Monthly savings on palbociclib in India vs USAPalbociclib (Ibrance) costs $12,000โ14,000/month in USA vs $500โ900/month in India โ annual savings $130,000+.
- 60%+India's share of global generic pharmaceutical supplyIndia is the world's pharmacy โ supplying generic drugs to over 200 countries including the USA, UK, and EU under national health service contracts.
Options for Accessing Indian Generic Hormone Therapy
There are several ways to access Indian generics โ each with different legal, quality, and practical considerations.
Legitimate Access Routes
- Travel to India for treatment and bring supplyMany patients travel to India for a consultation, obtain a local prescription, purchase a 3-6 month supply from a verified pharmacy, and return home. Personal import quantities (typically up to 90 days) are permitted by most countries.
- CancerFax-coordinated pharmacy accessCancerFax works with verified Indian pharmacies and can coordinate supply with proper prescription documentation for patients being managed by Indian oncologists.
- Patient assistance programmesFor branded drugs in the USA, manufacturer patient assistance programmes (e.g. Pfizer RxPathways for Ibrance) provide free or reduced-cost drugs for uninsured patients who meet income criteria.
Risks to Avoid
- Unverified online pharmaciesGeneric drugs from anonymous online pharmacies carry real counterfeit and contamination risks โ no regulatory oversight, no quality guarantee.
- Large commercial importationImporting large quantities commercially without proper drug import authorisation is illegal in most countries regardless of the drug's legality in India.
- Switching brands without oncologist knowledgeAlways inform your oncologist when changing drug source or manufacturer โ particularly important for drugs with narrow therapeutic windows.
Frequently Asked Questions
Accessing Indian Generics
Is it legal to bring Indian generic cancer drugs back to my country?
Most countries permit personal-use importation of up to 3 months of prescription medications for personal medical use. This is a recognised grey area โ technically regulated but typically not enforced for genuine personal medical supply. CancerFax advises on country-specific rules and can help with documentation for personal-use quantities.
How do I know the Indian generic is the real drug and not a counterfeit?
Purchase only from licensed pharmacies in India โ pharmacies registered with the State Drug Controller. CancerFax works exclusively with verified, licensed pharmacy chains that stock WHO-prequalified or USFDA-registered generics. Avoid purchasing from informal or online-only sources without verifiable physical premises.
Can I get enzalutamide in India without a prescription?
No โ enzalutamide (and all Schedule H oncology drugs in India) requires a valid prescription from a registered medical practitioner. CancerFax coordinates with Indian oncologists to provide proper prescriptions as part of the treatment coordination process.
More from the Hormone Therapy Resource Library
Explore generic quality guides, monitoring protocols, and how to access hormone therapy abroad.
- โ Hormone Therapy for Cancer โ Complete Guide
- Generic Hormone Therapy Drugs in India and China: Quality Guide
- Accessing Hormone Therapy Abroad Through CancerFax
- Monitoring During Hormone Therapy: Bone Density, PSA, and Tests
- CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib
- Enzalutamide vs Abiraterone vs Darolutamide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access Affordable Hormone Therapy Through CancerFax
CancerFax helps patients identify and access quality generic hormone therapy drugs in India โ with proper prescribing documentation, quality-verified supply, and ongoing medical coordination.
This content is for informational purposes only. Drug prices are approximate and vary by pharmacy and formulation. Always consult your oncologist before changing medication sources.